Nearly 6,750,000 people suffer moderate to severe cancer-related pain each year. Unfortunately, 10% to 15% of these patients fail to achieve acceptable pain relief with conventional management. Spinal cord stimulation (SCS) has been used with increased frequency for successful treatment of intractable cancer pain. We present two cases of intractable, refractoryto-conventional treatment cancer pain that were successfully treated with SCS. Case 1 reports a 51-year-old male with burning pain at the left groin site of inguinal metastases, post-surgical and intraoperative radiation therapy for treatment of squamous cell carcinoma of the anus. Case 2 reports a 43-year-old woman with intractable, burning, throbbing, and shooting pain, post-debulking followed by radiation of a metastatic colon carcinoma. In both cases SCS implantation provided 90% to 100% pain relief, improved functioning and sleep, and discontinuation of pain medications, sustained through 12 months.
The patient had used ibuprofen, acetaminophen, gabapentin, cyclobenzaprine, amitriptyline, and topical ointments, but they did not provide any relief. Because codeine, oxycodone, and hydrocodone had caused a rash in the past, the use of opioids was limited. Darvocet, fentanyl patches, and ilioinguinal and iliohypogastric nerve blocks provided the patient with minimal pain relief. He was counseled on alternative options of treatment, including an intrathecal drug delivery system and spinal cord stimulation (SCS). He chose SCS.
Once the decision has been made to proceed to SCS, a successful trial of percutaneous placement of temporary epidural leads must be performed before implantation of the entire SCS system. These temporary leads are connected to an external pulse generator, and patients typically wear them for a few days while performing their usual activities of daily living (ADLs) to fully assess the efficacy of the SCS trial. A realistic assessment presumes the enhancement of ADLs and decreased pain levels by 50% or more.
The surgical technique for final implantation of the SCS system is quite simple, requiring approximately 1 hour to perform the procedure in an ambulatory surgery setting. Like any surgical patient, patients who undergo SCS implantation are at risk for the standard surgical complications including bleeding, infection, cerebrospinal fluid leak, and hardware failure; however, these events are quite rare in experienced centers.
The patient successfully underwent a trial of percutaneous placement of two quadripolar epidural leads (Medtronic Inc, Minneapolis, MN) to level T8-T9 (figure 1). During the SCS trial, he reported good pain control (VAS score of 1 to 2 out of 10). Two weeks later, the patient underwent implantation with permanent leads and a Synergy generator (Medtronic Inc.). The procedure was done in ambulatory surgery, and his postoperative course was uneventful. The set stimulation parameters were amplitude of 3 to 6 volts, pulse width of 210 microseconds, and frequency of 100 Hz. The patient used the spinal cord stimulator continuously and reported 100% pain relief both at rest and with activities. He stopped using all pain medications and returned to his pre-neuropathy level of functioning. At 12-months post-implant, the patient continued to report good pain control (VAS scores 1 to 2 out of 10) and improved functional status.
Case 2
The patient is a 43-year-old woman who presented to the pain clinic with complaints of intractable, burning, throbbing, and shooting pain in her low back and right lower extremity that developed 3 months after debulking of a metastatic epidural tumor in the low thoracic spine from carcinoma of the colon followed by radiation therapy. The patient was not found to have recurrent metastatic disease. The pain was considered to be radiation induced. Reported VAS scores ranged from 5 to 9 out of 10. The patient tried various non-opioid and opioid analgesics, including ibuprofen, acetaminophen, codeine, oxycodone, hydrocodone, morphine, fentanyl patches, gabapentin, topiramate, tizanidine, clonidine patch, amitriptyline and topical ointments, all of which failed to provide significant pain relief. Moreover, a series of caudal epidural steroid blocks did not alleviate the severe neuropathic pain.
The patient was offered additional treatment options, including an intrathecal drug delivery system and spinal cord stimulator. She declined intrathecal pump placement and instead chose to proceed with placement of a spinal cord stimulator which she thought was a less invasive therapy. A trial of percutaneous placement as previously described for case 1 was undertaken prior to final placement of the SCS system. She successfully underwent a trial of percutaneous placement of two epidural quadripolar leads (Medtronic Inc) to level T9-T10 (figure 2). During the SCS trial, she reported adequate pain control with a VAS score of 1 out of 10. Three weeks later, she was implanted with permanent leads and a Synergy generator (Medtronic Inc). The procedure was done in ambulatory surgery, and her postoperative course was uneventful. The set stimulation parameters were amplitude of 2 to 7 volts, pulse width of 300 microseconds, and frequency of 60 Hz. The patient used the spinal cord stimulator continuously. After the surgery, she reported 90% to 100% pain relief, and she stopped using opioids. She reported an increased level of functioning and improved sleep. In the 12 months post-implant, the patient has reported sustained pain relief and continued improvements in functioning.
Discussion
Approximately 9 million people suffer from cancer-related pain each year, and nearly 75% of these people experience moderate-to-severe pain in the advanced and terminal stages of their disease. 1 The World Health Organization (WHO) guidelines for cancer pain management are based on a three-step ladder: (1) non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and acetaminophen for mild-to-moderate levels of cancer pain; (2) weak opioids for mild-to-moderate pain that does not respond to NSAIDs alone; and (3) strong opioids for moderate-to-severe levels of cancer pain. 2 Adjuvant medications, such as antiepileptics and tricyclic antidepressants, can also be added at any step of the ladder for optimal pain relief.
Unfortunately, approximately 10% to15% of patients with cancer-related pain do not achieve acceptable levels of pain relief with opiates alone or in combination with conventional adjuvant analgesics. 3 Unconventional agents and interventional management approaches have received considerable attention in an attempt to provide increased pain relief for patients with intractable cancer pain. SCS has been used with increased frequency for the treatment of intractable cancer pain.
SCS as an Analgesic
SCS was first used for pain control in 1967 by neurosurgeon Dr. Norman Shealy and his colleagues. 4 SCS is based on the principles enunciated in the "gate-control theory" of pain proposed by Melzack and Wall in 1965 . 5 This theory postulates that SCS activates large-diameter afferent fibers via application of an externally applied electric field that "closes the gate" to pain transmission. SCS blocks pain by stimulating the dorsal columns, which inhibits transmission through the pain-conducting spinothalamic tract. The electrical pulse wave is generated either with an external neuropulse generator that transmits the electrical pulse via a cable to an antenna worn externally which is radiocoupled to an implanted receiving device or with an implanted, programmable neuropulse generator. The newly developed programmable generators contain an antenna, computer module, and a non-rechargeable or rechargeable battery pack which can last up to 9 years. By placing an electrode array to different segments of the spinal cord, the patient's subjective pain can be controlled in nearly all areas of the body, from C1-C2 for facial pain, to T7 for abdominal pain, or to T8-T9 for low back and radicular pain.
Since its first use over 3 decades ago, in which electrodes were placed epidurally over the dorsal columns of the spinal cord, SCS has been further refined, and multiple studies have demonstrated its efficacy in the treatment of intractable, chronic pain with a variety of causes. 6 SCS has been used to successfully treat chronic pain in patients with failed back syndrome, 7, 8 ischemic limb pain, 9 angina pectoris, 10 and painful peripheral neuropathies. 11, 12 SCS for Cancer Pain It has been estimated that approximately 15% to 40% of chronic cancer pain has a neuropathic component, 13 and neuropathic pain often responds poorly to opioids. Moreover, the side effect profile of opioids and other analgesics often warrant other interventional pain management approaches. SCS for cancer pain has been receiving recent attention as a safe and efficacious treatment option.
There are other reports about the pain-alleviating effect of SCS for patients with cancer pain. Cata et al 14 reported the benefits of SCS for chemotherapy-induced pain in two patients whose pain had been poorly controlled with conventional medications. Both patients reported pain relief of more than 50%, improved gait, and decreased daily requirements of pain medications after SCS. Similarly, Hamid and Haider 15 reported on the adequate pain control achieved with SCS in a patient with intractable neuropathic pain secondary to radiation-induced transverse myelitis unresponsive to other pain management interventions.
Conclusion
We present two cases of intractable, refractory-toconventional treatment cancer pain which were successfully treated with SCS. This technique may be a therapeutic alternative for patients who have exhausted all available treatments or who have an increased risk for or prefer not to have more invasive interventions. There are no risks for potential neurologic dysfunctions which can complicate ablative procedures. With this method of treatment, our patients had satisfactory symptom relief, an increase in ADLs and discontinuation of pain medications. In our opinion, SCS is a relatively easy to perform, effective, and safe procedure and is reversible should patients lose its pain-alleviating effect. Moreover, if SCS fails to provide the expected level of pain relief, patients are not required to undergo the uncomfortable weaning process associated with intrathecal or epidural pain medications.
SCS is an important adjuvant treatment in patients with intractable neuropathic cancer pain, which may make its own niche in the therapy algorithm for this group of patients. These two cases presented here represent additional evidence and support for utilizing SCS in the treatment of refractory neuropathic cancer pain.
